Any time a stock moves down 75% over a given period of time, investors have reason to be concerned. When such a move happens in a given trading day, it’s time to ring the alarm bells. For investors in ...

Japanese biotech Ono Pharmaceutical is acquiring Deciphera Pharmaceuticals for $2.4 billion, the companies announced Monday. The move serves to bolster Ono’s cancer pipeline, with oncology pinpointed ...

The MarketWatch News Department was not involved in the creation of this content. -- Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled ...

On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera ...

Deciphera Pharmaceuticals’ DCPH shares surged 74.3% in the past month after the cancer-focused, commercial-stage biopharmaceutical company announced entering into a definitive merger agreement with ...

Short selling biotechnology stocks is a dangerous game to play. However, Deciphera Pharmaceuticals (NASDAQ:DCPH) has been a boon to the bears as DCPH stock is far below its peak price. Source: Iryna ...

Our estimates show that Qinlock 2L KIT exon 11+17/18 mutation indication sales guidance is unlikely to be achieved due to fractional incidence. Deciphera Pharmaceuticals is expecting a Phase III ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on advanced kinase inhibitor treatments targeting the tumor cell and the tumor ...

– Net Proceeds of $163.4 Million from Public Offering in April, Enabling the Company to Fund Operating and Capital Expenditures into 2025 – – Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT ...

WALTHAM, Mass.-- (BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today ...